66 varieties of national supply, involving 25 well-known pharmaceutical companies

"
Pharmaceutical Network Industry Dynamic" Recently, Shanxi Province Pharmaceutical Sei central bidding procurement network issued two consecutive notices that Chenxin Pharmaceutical Co., Ltd., Chengdu Diao Pharmaceutical Group Co., Ltdand other 25 pharmaceutical production enterprises of 66 product regulations, apply for the cancellation of direct-hanging network product platform online qualificationIt is worth noting that the Notice shows that the relevant drug companies provide a national commitment to unified non-supply, which means that these products will gradually withdraw from the national pharmaceutical marketspecific ally, the withdrawal of 66 varieties in Shanxi Province, including double yellow even particles, carlyine capsules, forefront of Kangshu capsules, glucose injections, etc, are clinically large varieties, and involved in the Ha Pharmaceutical Group, Stone Pharmaceutical Group, Chenxin Pharmaceutical sand and many other well-known companieson the root causes of these pharmaceutical companies to withdraw their products from the market, some analysts pointed out that, or mainly because in recent years, drug review and approval system reform to encourage pharmaceutical innovation, with volume procurement squeeze dry intermediate link moisture, cut off belt gold sales chain, consistency evaluation to promote the clinical replacement of generic drugs high-priced original drugs, as well as focus on monitoring and strengthening clinical rational drug use and other policies, China's pharmaceutical market pattern is undergoing drastic changescoupled with production costs, raw material costs and other rising prices, many enterprises in the production process appeared in part of the small-scale variety cost inversion phenomenon, making it impossible to maintain the basic operationIn addition, at present, many drug prices are still being continued to be under pressure, once the winning bid price of drugs is overwhelming the cost of the price below, the product is even less able to establish a foothold in the marketThe combination of various factors led to a large number of drugs abandoned, pharmaceutical companies were forced to abandon the marketin fact, pharmaceutical enterprises actively apply for product cancellation of the network, has been a common phenomenon in the pharmaceutical industry in the past two yearsSince this year, there have been a large number of products in the pharmaceutical company's application to withdraw from the marketfor example, on January 8 this year, Hainan Province Pharmaceutical Central Procurement Center issued a notice on the withdrawal of some drugs (2020.01.08) (2020.01.08), 250 pharmaceutical applications to cancel the internetAmong them, 171 drugs are due to rising production costs, can not be normal supply, production line transformation, production line stop and other reasons lead to production stoppage, 28 drugs due toraw materials price increaseor or shortage led to the shutdown, 15 drugs are due to the winning bid and cost inversion led to the shutdown January 22, Ningxia Drug Central Procurement Network issued a notice, will cancel the Erdostam capsules and other 48 product-standard drugs winning the bid (hanging net) qualification Of these, 46 drugs applied for the cancellation of the internet, and 2 applications for scrap industry insiders believe that compared to previous years, products through marketing, price war, can be based in the market "boom", has become yesterday's yellow flower In the future, through the promotion of national medical reform, enterprise response, the concentration of the drug market will gradually strengthen, the head effect will be more obvious, and the price of drugs can become more reasonable.